The Josep Carreras Leukaemia Research Institute (IJC) is a comprehensive cancer research center dedicated to conduct research and drive innovation in the epidemiological, preventive, clinical, translational, and basic aspects of leukaemia and other hematologic malignancies, with the final aim of finding a cure for these diseases. It was created in 2010, and since then has experienced an exponential growth.

The IJC is also part of the network of Excellence Research Centers of Catalonia (CERCA) and was accredited as a Severo Ochoa Center of Excellence by the Ministry of Science, Innovation, and Universities in 2024. Since 2018, the Institute has also been accredited by the Scientific Foundation of the Spanish Association Against Cancer (FCAECC) Additionally, IJC is one of the centers integrated into the Institut de Recerca Germans Trias i Pujol (IGTP) accreditation as Accredited Health Research Institute (IIS) by the Carlos III Health Institute (ISCIII).

The IJC's main headquarters is located within the Can Ruti Biomedical Campus, alongside other leading biomedical institutions, providing direct access to cutting-edge scientific and technological facilities, as well as complementary community services. The IJC has six locations integrated into reference hospitals: Hospital Germans Trias i Pujol, Hospital Clínic, Hospital Sant Pau, Hospital Josep Trueta, Hospital del Mar and Hospital San Joan de Déu. This facilitates close collaboration between basic and clinical researchers, fostering translational research that integrates basic science with clinical practice in clinical settings.

The Josep Carreras Leukemia Research Institute is looking for a Postdoctoral Researcher to join our dynamic team as part of the project PID2023-150280OB-I00, which aims to unravel the role of luminal lineage in the progression of triple-negative breast cancer. This position will be based at our Can Ruti campus in Badalona.

RESEARCH DESCRIPTION

A postdoctoral researcher position is offered to coordinate a project of the Cancer Heterogeneity and Hierarchies Group led by Dr Verónica Rodilla, at the Institut de Recerca contra la Leucèmia Josep Carreras, Badalona.

The work will focus on the LiLum project, a groundbreaking initiative designed to explore the role of luminal lineages in TNBC progression. Using state-of-the-art lineage tracing, molecular, and bioinformatics approaches, the project aims to identify and validate the molecular drivers of clonal expansion and metastasis formation in TNBC.

MAIN RESPONSABILITIES

• Conduct in vivo and in vitro experiments, including lineage tracing, organoid cultures, and drug screening.
• Perform high-throughput sequencing analyses and bioinformatics interpretations.
  Collaborate with internal units such as Bioinformatics, Proteomics, and the Single Cell Unit.
• Present findings at national and international conferences and contribute to high-impact publications.
• Supervise and mentor junior team members, including PhD and master’s students.

WHAT WE NEED

• A highly motivated individual with a PhD in a relevant biomedical field (cancer biology, molecular biology, or a related discipline).
• Strong experience in molecular biology techniques and in vivo models; expertise in bioinformatics and/or single-cell transcriptomics is highly valued.
• Knowledge of cancer biology, particularly breast cancer or tumor heterogeneity, is a plus.
• Excellent organizational skills, a proactive attitude, and strong teamwork capabilities.
• Proven ability to work independently and solve complex problems creatively.
• Excellent communication skills in English, both written and verbal.

WHAT WE OFFER

• A 3-year full-time contract.
• The opportunity to work in a cutting-edge research environment with access to state-of-the-art facilities.
• A dynamic, multidisciplinary team with opportunities for collaboration and professional growth.
• Participation in the LiLum project, which has high translational potential and aligns with major challenges in oncology research.
• Competitive salary aligned with qualifications and experience.
• Starting March 1st, 2025.

DEADLINE

Please submit your application by 15th Feb 2025.

WHO WE ARE?

What makes us different?

The mission of the Josep Carreras Institute is to conduct research and drive innovation in the epidemiological, preventive, clinical, translational, and basic aspects of leukaemia and other hematologic malignancies, with the final aim of finding a cure for these diseases.
The IJC’s vision is to be a world-class reference and excellent research multicampus that contributes to the improvement of results, and the cure of patients affected by leukemia and other malignant hemopathies, through innovation, sustainability, social responsibility, talent, and professional experience.

HR Excellence

In 2019, IJC was honored with the “Human Resources Excellence in Research Award” by the European Commission, recognizing the alignment of our human resources policies with the European Charter for Researchers and Code of Conduct for the Recruitment of Researchers. The Human Resources Strategy for Researchers (HRS4R) guides research centers of excellence in implementing and upholding these standards within their policies, emphasizing training, professional development, and mobility opportunities.
The IJC’s commitment to these values and principles strengthens our internal policies and ensures that our members have the optimal conditions and environment for their professional development.
The Board of Trustees is composed of representatives of the Generalitat de Catalunya (regional government), University of Barcelona, Autonomous University of Barcelona, the City of Badalona and the Jose Carreras International Leukaemia Foundation
The Catalan government provides hard money on an annual basis. The Jose Carreras International Leukaemia Foundation provides start-up funds, project funds as well as financial support for investments.
The JCI has an international scientific advisory board served by prominent researchers from US and Europe.
The IJC has been awarded ERC and other EU grants.

The IJC is an equal-opportunity employer. We evaluate qualified applicants without regard to race, color, religion, sex, national origin, disability, or other legally protected characteristics.